[Skin tests and chymopapain-specific immunoglobulins E after chemonucleolysis].
Skin tests (prick tests) with chymopapain were performed on 3 groups of patients: 75 patients awaiting chemonucleolysis with chymopapain (group I), 42 of these 75 patients 2-3 weeks after chemonucleolysis (group II), and 60 atopic patients suffering from asthma and/or rhinitis with positive skin tests to at least one of the airborne allergens (group III). A positive skin test was found in one patient of group I (1.33%), one patient of group III (1.7%) and 11 patients of group II (26.2%). Thus, sensitization to chymopapain is not more frequent among atopic patients, and chemonucleolysis has a highly significant (P less than 0.001) sensitizing effect. Chymopapain-specific IgE's were found in one out of 75 patients (1.33%) before, and in 14 out of 45 patients (31%) after chemonucleolysis; the difference was significant (P less than 0.001). Concordance between skin tests and specific IgE's reached the 74% level. Our results are consistent with those of the literature. They show that prick tests with a 10 mg/ml solution of chymopapain constitute, for the time being, a simple, reliable and cheap method for detecting subjects at risk.
D000328:Adult; D000368:Aged; D002917:Chymopapain / Q000009:adverse effects / Q000276:immunology*; D004342:Drug Hypersensitivity / Q000517:prevention & control; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology; D007073:Immunoglobulin E / Q000032:analysis*; D007404:Intervertebral Disc Chemolysis / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011852:Radioallergosorbent Test; D012306:Risk; D012882:Skin Tests
D007073:Immunoglobulin E; D002917:Chymopapain
Tests cutanés et immunoglobulines E spécifiques à la chymopapaïne après chimionucléolyse.